吗替麦考酚酯与口服环磷酰胺对皮肤厚度疗效的随机对照试验事后分析
基于硬皮病肺研究SLS I和II的事后分析,评估吗替麦考酚酯(MMF)与环磷酰胺(CYC)对改良Rodnan皮肤评分(MRSS)的影响。在SLS II中,MMF和CYC均与弥漫性皮肤型系统性硬化(dcSSc)患者24个月内MRSS较基线的显著改善相关,两组间无差异;与SLS I安慰剂组相比,MMF和CYC在12、18、24个月时MRSS改善有统计学意义。
要点
- MMF和CYC均改善dcSSc患者24个月内MRSS,两组间无差异。
- 与SLS I安慰剂相比,MMF和CYC在12、18、24个月MRSS改善显著。
- SLS II基线平均MRSS:CYC组14.0±10.6,MMF组15.3±10.4。
核心结论
- 在SLS II中,MMF和CYC治疗使dcSSc患者24个月内MRSS改善。
- 与SLS I安慰剂组相比,MMF和CYC治疗使dcSSc患者MRSS改善有统计学意义。
研究设计与样本
- SLS I参与者每日口服CYC或匹配安慰剂1年。
- SLS II参与者每日MMF用2年,或每日口服CYC用1年后第2年用安慰剂。
- 采用线性混合模型比较SLS II中CYC和MMF组与SLS I安慰剂组dcSSc患者24个月内MRSS变化。
主要发现
- SLS II中dcSSc患者CYC和MMF组MRSS较基线在24个月内各时间点均有统计学显著改善(P < 0.05)。
- SLS II中CYC与MMF两组间MRSS改善无差异。
- dcSSc亚组中,SLS II各组(MMF、CYC、合并队列)与SLS I CYC组至各6个月访视的MRSS变化相似。
- 与SLS I安慰剂组相比,SLS II各组在12、18、24个月MRSS改善有统计学意义(P < 0.05)。
关键数值与推荐
- SLS II基线平均±SD MRSS:CYC组14.0±10.6单位,MMF组15.3±10.4单位。
- SLS II中58.5%归类为dcSSc。
临床怎么用
- 对于dcSSc患者,MMF或口服CYC可作为改善皮肤厚度的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy of mycophenolate mofetil (MMF) and cyclophosphamide (CYC) on modified Rodnan skin score (MRSS) in participants enrolled in the Scleroderma Lung Study (SLS) I and II. METHODS: SLS I participants received daily oral CYC or matching placebo for 1 year, whereas SLS II participants received daily MMF for 2 years or daily oral CYC for 1 year followed by placebo for second year. We assessed the impact of MMF and CYC on the MRSS in SLS II over a 24-month period. We also compared the change in MRSS in patients with diffuse cutaneous systemic sclerosis (dcSSc) assigned to CYC and MMF in SLS II and SLS I versus placebo in SLS I over a 24-month period using a linear mixed model. RESULTS: In SLS II, the baseline mean ± SD MRSS was 14.0 ± 10.6 units for CYC and 15.3 ± 10.4 units for MMF; 58.5% were classified as dcSSc. CYC and MMF were associated with statistically significant improvements in MRSS from baseline over the period of 24 months in dcSSc (P < 0.05 at each time point), but there were no differences between the 2 groups. In the dcSSc subgroup, the change in MRSS from baseline to all 6-month visits was similar in SLS II groups (MMF, CYC, pooled cohort [MMF + CYC]) and in the SLS I CYC group and showed statistically significant improvements compared to SLS I placebo at 12, 18, and 24 months (P < 0.05). CONCLUSION: In SLS II, MMF and CYC treatment resulted in improvements in MRSS in patients with dcSSc over 24 months. In addition, MMF and CYC treatment resulted in statistically significant improvements in MRSS in patients with dcSSc when compared with the SLS I placebo group.
引用
- Namas R, Tashkin DP, Furst DE, et al. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. Arthritis Care Res (Hoboken). 2018. PMID: 28544580. doi:10.1002/acr.23282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。